Sanam Singh is a Grade 12 student and the Head Girl at TMS School in Richmond Hill.

I was honored to have been accepted into the Harvard Summer School program this past July. As someone aspiring toward a legal career, my time on Harvard’s campus Ěýwas wonderful and extremely memorable.

The program participants did not know each other, but were required to work together on an assigned project. This meant that we all had to leverage our strengths and weaknesses to work towards a collective goal. Harvard’s unique teaching style gave me the opportunity to bond with like-minded students and create strong friendships during this short time. This allowed us, as a group, to formulate a successful and innovative mock business model.

The final project of this course required a solid understanding of the components of a successful start-up business, including finances, marketing and branding, and intellectual property law.

Takeaways & Learnings

One interesting lecture was on the importance of intellectual property in the early stages of a business. Reflecting back on the process, it is clear how a company needs to value its IP assets in order for its sustainable growth.

Personally, it was very valuable to have hands-on experience for dealing with the ambiguities of IP rights in marketing. For example, many companies have similar marketing strategies, especially when the products are similar in nature. While creating our business model, my group and I brainstormed many distinct styles of marketing the end product.

From this experience, I gained a better understanding of IP rights and their crucial role in the marketing and branding strategies which contribute to a business plan.

Final Remarks & Conclusions:

In conclusion, I learned so much about start-ups and the components that contribute to a start-up's success. Being able to work with a variety of students to meet a common goal, create a business plan and apply our learned concepts made this experience even more memorable.

Prior to this course, I was not fully aware of how important IP was for businesses and start-ups. After developing a mock business model and learning to think like both a lawyer and businesswoman, I feel confident in one day being able to implement these learnings into future ventures.

I am so grateful and honored to have been selected to attend this Harvard program as I had such a remarkable experience. Harvard’s teaching methods, interaction and communication are unlike any educational experience I have had. Working with complete strangers to come up with a realistic and functional business in such a short amount of time taught me a myriad of intangible skills, tools, and ideas that I can apply to so many different aspects of my life.

The post Summer at Harvard: A high school student's perspective appeared first on IPOsgoode.

Photo by Sangharsh Lohakare ()

Emily Prieur is an IPilogue Writer and a 3L JD Candidate at Queen’s University Faculty of Law.

Ěý

Introduction

In to Drs. Emmanuelle Charpentier and Jennifer A. Doudna for “the development of a method for genome editing” otherwise known as CRISPR gene editing.

CRISPR’s discovery was a revolutionary breakthrough that has the potential to . CRISPR has been widely discussed within the scientific community for years for both its scientific and .

But in late February 2022, CRISPR entered the news for an entirely different reason. After a decade-long dispute, the United States that Drs. Charpentier and Doudna were not the rightful owners of the CRISPR-Cas9 patent, concluding that the gene editing technology belonged to Dr. Feng Zheng and his team of scientists at the Broad Institute of MIT and Harvard.

What is CRISPR?

CRISPR is an acronym for “” and Cas9 is short for “CRISPR-associated protein 9”. CRISPR are specialized repeats of genetic information (i.e., DNA). . The protein that is added to the DNA ; however, it is the protein that is most often used by scientists when employing this technique. In essence, the finding a “bad” piece of DNA, removing that bad piece, and then correcting the DNA sequence by inserting a new gene.

The Patent Dispute History

Drs. Charpentier and Doudna from the University of California-Berkeley (“UCB”) showed the genius of the CRISPR editing method in their paper in 2012, specifically on gene-editing in test tubes. Dr. Zhang and his group at the Broad Institute of MIT and Harvard also published in in 2013, showing the promise of CRISPR/Cas9 in humans.

Following the scientists’ publications, the United States transitioned from a first to invent patent system to a first inventor to file system, . This is relevant as all patent disputes between the scientists revolved around the issue of who invented CRISPR, and, more specifically, who was able to prove CRISPR’s application in humans, first.

In 2014, the United States Patent and Trademark Office (“USPTO”) granted U.S. Patent to Dr. Zhang and his group at the Broad Institute of MIT and Harvard. There were two interferences at the PTAB, in 2015 and 2019, both triggered by the UCB through and For the first interference, the that there was no interference because of the invention’s (i.e., eukaryotic human cells versus non-human cells in a test tube). For the second interference, UCB requested that the PTAB reverse the prior first instance decision and conclude that successful experiments in human cells is not necessary to successfully obtain the patent.

The PTAB’s Decision

Following the scientists’ oral arguments on February 4, 2022, the that Dr. Zheng and his team at the Broad Institute of MIT and Harvard were the rightful owners of the patent. UCB was unable to prove that their invention was applicable in human cells prior to the Broad Institute’s invention in 2013.

Conclusion

The battle may not be over. Drs. Charpentier and Doudna, along with the University of California Berkley, have the option to appeal to the U.S. Court of Appeals Federal Circuit. In a , the University of California Berkley said it was to challenge the PTAB decision, making an appeal even more likely. In addition to UCB, Dr. Zheng and his colleagues at the Broad Institute of MIT and Harvard are also embroiled in

The post Nobel Prize Winners of CRISPR/Cas9 Lose Decade Long Patent Battle to the Broad Institute of MIT and Harvard appeared first on IPOsgoode.